论文部分内容阅读
慢性乙型肝炎病毒(hepatitis B virus,HBV)感染是肝硬化的重要原因。研究显示,有效抑制HBV复制可改善肝纤维化[1-2],延缓或阻止代偿期肝硬化向失代偿期的进展,减少失代偿期患者病情进一步恶化,减少门静脉高压及相关并发症发生[3-6],延长生存期[3-4]。因此,有效的抗病毒治疗对改善疾病临床结局具有重要意义[7],也是目前HBV相关肝硬化整体治疗策略中的一个重要组成部分。近年来,我国、亚太、欧洲和美国肝病学会
Chronic hepatitis B virus (HBV) infection is an important cause of cirrhosis. Studies have shown that effective inhibition of HBV replication can improve liver fibrosis [1-2], delay or prevent the progression of decompensated cirrhosis to decompensation, reduce the deterioration of patients with decompensated diseases, reduce portal hypertension and related complications Disease occurs [3-6], prolong survival [3-4]. Therefore, effective antiviral therapy is of great importance in improving the clinical outcome of the disease [7] and is also an important part of the overall treatment strategy for HBV-related cirrhosis. In recent years, China, Asia Pacific, Europe and the United States Liver Society